Related Experiment Video
Updated: Jun 15, 2026
09:17
Using Retinal Imaging to Study Dementia
Published on: November 6, 2017
DHA may prevent age-related dementia.
Greg M Cole1, Sally A Frautschy
1Departments of Medicine and Neurology, University of California, Los Angeles, CA 90095, USA. gmcole@ucla.edu
The Journal of Nutrition
|February 26, 2010
Summary
Docosahexaenoic acid (DHA) may slow dementia progression by targeting multiple pathways involved in Alzheimer's disease. Early nutritional intervention with DHA and antioxidants shows promise for dementia prevention.
Area of Science:
- Neuroscience
- Nutritional Science
- Gerontology
Background:
- Dementia risk, particularly Alzheimer's disease (AD), escalates with age, posing a significant global health challenge.
- Existing prevention strategies are limited, necessitating safe, effective, and affordable interventions.
- The aging global population projects a substantial increase in dementia cases, highlighting the urgency for proactive measures.
Purpose of the Study:
- To review the potential of docosahexaenoic acid (DHA), an omega-3 fatty acid, in mitigating dementia pathogenesis.
- To explore DHA's multi-faceted mechanisms in potentially slowing Alzheimer's disease and vascular dementia progression.
- To assess the current evidence for DHA supplementation in early-stage dementia and advocate for future research directions.
Main Methods:
- Review of existing scientific literature on docosahexaenoic acid (DHA) and its role in dementia.
- Analysis of DHA's molecular actions on key pathological pathways in Alzheimer's disease (AD).
- Evaluation of clinical trial data regarding DHA or fish oil supplementation for dementia.
Main Results:
- DHA exhibits pleiotropic effects, including reducing beta-amyloid production and moderating tau hyperphosphorylation.
- DHA may counteract neuroinflammation, oxidative stress, and insulin/neurotrophic factor signaling deficits implicated in dementia.
- Clinical studies suggest DHA/fish oil may slow early dementia progression, potentially influenced by apolipoprotein E genotype.
Conclusions:
- Docosahexaenoic acid (DHA) demonstrates significant potential as a preventative agent against dementia.
- Further large-scale clinical trials are required to confirm DHA's efficacy, particularly in the prodromal stages of dementia.
- Advocacy for early nutritional intervention using defined supplements containing DHA and antioxidants is supported by current findings.
Related Concept Videos
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...